Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections
- 22 August 2012
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 167 (2), 324-352
- https://doi.org/10.1111/j.1476-5381.2012.02057.x
Abstract
β-amyloid (Aβ) is widely accepted to be one of the major pathomechanisms underlying Alzheimer's disease (AD), although there is presently lively debate regarding the relative roles of particular species/forms of this peptide. Most recent evidence indicates that soluble oligomers rather than plaques are the major cause of synaptic dysfunction and ultimately neurodegeneration. Soluble oligomeric Aβ has been shown to interact with several proteins, for example glutamatergic receptors of the NMDA type and proteins responsible for maintaining glutamate homeostasis such as uptake and release. As NMDA receptors are critically involved in neuronal plasticity including learning and memory, we felt that it would be valuable to provide an up to date review of the evidence connecting Aβ to these receptors and related neuronal plasticity. Strong support for the clinical relevance of such interactions is provided by the NMDA receptor antagonist memantine. This substance is the only NMDA receptor antagonist used clinically in the treatment of AD and therefore offers an excellent tool to facilitate translational extrapolations from in vitro studies through in vivo animal experiments to its ultimate clinical utility.Keywords
This publication has 243 references indexed in Scilit:
- Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s DiseaseCellular and Molecular Neurobiology, 2011
- Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cellsNeuroscience Letters, 2010
- Memantine lowers amyloid‐β peptide levels in neuronal cultures and in APP/PS1 transgenic miceJournal of Neuroscience Research, 2009
- Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imagingJournal of Neuroscience Research, 2008
- Mechanism of Ca2+ Disruption in Alzheimer's Disease by Presenilin Regulation of InsP3 Receptor Channel GatingNeuron, 2008
- Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In VivoNeuron, 2008
- Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behaviorBehavioural Brain Research, 2008
- Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomersNeurobiology of Aging, 2007
- AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine LossNeuron, 2006
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004